Why the study?
Does the use of neurohormonal antagonists and loop diuretics affect cardiorenal biomarkers and clinical outcomes in patients with HFrEF?
Does the use of neurohormonal antagonists and loop diuretics affect cardiorenal biomarkers and clinical outcomes in patients with HFrEF?
ACE inhibitors and ARBs show beneficial effects on cardiac, inflammatory, and renal tubular biomarkers in HFrEF, suggesting they should not be withheld solely based on glomerular function, whereas increasing diuretic doses marks disease progression.
No takes yet. Share an insight, caveat, or question.
Higher diuretic doses may mark HFrEF progression; observational data leaves open causality for biomarkers and outcomes.
Branković et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: